6600 — SciClone Pharmaceuticals (Holdings) Share Price
Last trade - 00:00- HK$11.81bn
- HK$9.70bn
- CNY3.16bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.89 | ||
| PEG Ratio (f) | 1.67 | ||
| EPS Growth (f) | 5.61% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.36 | ||
| Price to Tang. Book | 3.83 | ||
| Price to Free Cashflow | 8.27 | ||
| Price to Sales | 3.48 | ||
| EV to EBITDA | 6.42 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 36.5% | ||
| Return on Equity | 35.86% | ||
| Operating Margin | 38.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 1,708.07 | 1,918.56 | 2,518.47 | 2,749.68 | 3,155.61 | 3,613 | 4,153.02 | 17.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +14.88 | +59.94 | -2.67 | -5.39 | +39.74 | -1.27 | +13.02 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.
Directors
- Zhenfu Li NEC (57)
- Hong Zhao PRE (57)
- Rongrong Pan CFO (42)
- Yansong Chang VPR (52)
- Xiaoning Guo VPR (42)
- Min Jia VPR (49)
- Chihwen Shao VPR (57)
- Lianzong Wu VPR (46)
- Mingxiang Wu VPR (54)
- Sin Man Chan SEC (34)
- Quan Li NED (40)
- Yi-Hsien Lin NED (38)
- Cen Shi NED (45)
- Daniel Vasella NED (68)
- Haixia Wang NED
- Ping Chen NID (62)
- Yushao Gu NID (51)
- Wendy Hayes NID (51)
- Guoen Liu NID (64)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 13th, 2020
- Public Since
- March 3rd, 2021
- No. of Employees
- 1,050
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 630,296,632
- Address
- 22/F, SHANGHAI
- Web
- https://www.sciclone.com/
- Phone
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 6600
Similar to 6600
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 11:09 UTC, shares in SciClone Pharmaceuticals (Holdings) are trading at HK$18.72. This share price information is delayed by 15 minutes.
Shares in SciClone Pharmaceuticals (Holdings) last closed at HK$18.72 and the price had moved by +68.65% over the past 365 days. In terms of relative price strength the SciClone Pharmaceuticals (Holdings) share price has outperformed the FTSE Developed Asia Pacific Index by +61.38% over the past year.
The overall consensus recommendation for SciClone Pharmaceuticals (Holdings) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSciClone Pharmaceuticals (Holdings) does not currently pay a dividend.
SciClone Pharmaceuticals (Holdings) does not currently pay a dividend.
SciClone Pharmaceuticals (Holdings) does not currently pay a dividend.
To buy shares in SciClone Pharmaceuticals (Holdings) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$18.72, shares in SciClone Pharmaceuticals (Holdings) had a market capitalisation of HK$11.80bn.
Here are the trading details for SciClone Pharmaceuticals (Holdings):
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6600
Based on an overall assessment of its quality, value and momentum SciClone Pharmaceuticals (Holdings) is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in SciClone Pharmaceuticals (Holdings) is HK$17.94. That is 4.17% below the last closing price of HK$18.72.
Analysts covering SciClone Pharmaceuticals (Holdings) currently have a consensus Earnings Per Share (EPS) forecast of CNY1.84 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SciClone Pharmaceuticals (Holdings). Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +39.82%.
As of the last closing price of HK$18.72, shares in SciClone Pharmaceuticals (Holdings) were trading +37.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The SciClone Pharmaceuticals (Holdings) PE ratio based on its reported earnings over the past 12 months is 8.89. The shares last closed at HK$18.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
SciClone Pharmaceuticals (Holdings)'s management team is headed by:
- Zhenfu Li - NEC
- Hong Zhao - PRE
- Rongrong Pan - CFO
- Yansong Chang - VPR
- Xiaoning Guo - VPR
- Min Jia - VPR
- Chihwen Shao - VPR
- Lianzong Wu - VPR
- Mingxiang Wu - VPR
- Sin Man Chan - SEC
- Quan Li - NED
- Yi-Hsien Lin - NED
- Cen Shi - NED
- Daniel Vasella - NED
- Haixia Wang - NED
- Ping Chen - NID
- Yushao Gu - NID
- Wendy Hayes - NID
- Guoen Liu - NID